Educational information, not medical advice — ask your doctor or midwife.
Bremelanotide, sold as Vyleesi, is a synthetic peptide that works directly in the brain to boost sexual desire rather than acting on blood flow or hormones like most other treatments. It was FDA-approved in 2019 for premenopausal women with acquired, generalized HSDD — meaning low desire that developed over time and causes real distress. Unlike a daily pill, it is injected about 45 minutes before anticipated sexual activity on an as-needed basis.
Bremelanotide activates melanocortin receptors (particularly MC3R and MC4R) in the brain — areas linked to sexual arousal, motivation, and reward. Think of it as flipping on a 'desire signal' in the brain rather than relaxing blood vessels or adjusting hormone levels. This central mechanism is why it can increase desire even when hormonal levels are normal.
Bremelanotide comes as a single-use, prefilled auto-injector pen delivering 1.75 mg subcutaneously (under the skin of the abdomen or thigh). It is not available as an oral supplement or over-the-counter product. Compounded versions of PT-141 are available through some specialty pharmacies but are not FDA-approved for this indication.
Originally investigated as a potential tanning agent (it does cause some skin darkening), bremelanotide was accidentally discovered to produce spontaneous erections in male researchers during early trials. This led to two decades of clinical development for sexual dysfunction in both men and women, culminating in FDA approval for HSDD in women in June 2019.
Evidence grades and traditional-use labels are explained in our methodology. Nothing here is medical advice.
What it is typically used for, usual dose, cautions, and the study behind it where real trial data exists.
One email with the summary. We'll also send a short weekly evidence update — unsubscribe any time.